BB&T Securities LLC lowered its position in shares of Mednax, Inc (NYSE:MD) by 5.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 97,492 shares of the company’s stock after selling 5,415 shares during the period. BB&T Securities LLC owned 0.10% of Mednax worth $4,203,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Pacer Advisors Inc. increased its stake in Mednax by 8.1% during the 2nd quarter. Pacer Advisors Inc. now owns 1,940 shares of the company’s stock worth $117,000 after acquiring an additional 145 shares during the period. Commonwealth Bank of Australia increased its stake in Mednax by 15.3% during the 2nd quarter. Commonwealth Bank of Australia now owns 2,205 shares of the company’s stock worth $132,000 after acquiring an additional 293 shares during the period. Fuller & Thaler Asset Management Inc. bought a new position in Mednax during the 3rd quarter worth $103,000. Daiwa Securities Group Inc. increased its stake in Mednax by 20.0% during the 2nd quarter. Daiwa Securities Group Inc. now owns 3,000 shares of the company’s stock worth $181,000 after acquiring an additional 500 shares during the period. Finally, Meiji Yasuda Asset Management Co Ltd. bought a new position in Mednax during the 2nd quarter worth $217,000. Hedge funds and other institutional investors own 98.44% of the company’s stock.

In other news, insider John C. Pepia sold 3,000 shares of Mednax stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $42.85, for a total value of $128,550.00. Following the completion of the transaction, the insider now directly owns 35,569 shares of the company’s stock, valued at approximately $1,524,131.65. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Cesar L. Alvarez sold 10,668 shares of Mednax stock in a transaction dated Friday, November 3rd. The stock was sold at an average price of $42.59, for a total value of $454,350.12. Following the completion of the transaction, the director now directly owns 44,215 shares of the company’s stock, valued at $1,883,116.85. The disclosure for this sale can be found here. Company insiders own 2.40% of the company’s stock.

Mednax, Inc (MD) opened at $50.60 on Friday. The company has a market capitalization of $4,738.94, a PE ratio of 15.47, a price-to-earnings-growth ratio of 1.63 and a beta of 0.39. Mednax, Inc has a twelve month low of $40.56 and a twelve month high of $72.13. The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 0.62.

Mednax (NYSE:MD) last announced its earnings results on Wednesday, November 1st. The company reported $0.87 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.87. Mednax had a return on equity of 10.80% and a net margin of 7.76%. The firm had revenue of $868.95 million for the quarter, compared to the consensus estimate of $864.78 million. During the same period in the previous year, the business earned $1.09 EPS. The business’s quarterly revenue was up 4.9% compared to the same quarter last year. equities analysts anticipate that Mednax, Inc will post 3.1 earnings per share for the current fiscal year.

MD has been the topic of a number of recent research reports. Robert W. Baird restated a “hold” rating and set a $47.00 price objective on shares of Mednax in a research note on Sunday, September 3rd. KeyCorp raised Mednax from a “sector weight” rating to an “overweight” rating and set a $51.00 target price on the stock in a report on Sunday, September 17th. BMO Capital Markets began coverage on Mednax in a report on Monday, October 16th. They issued a “market perform” rating and a $46.00 target price on the stock. Jefferies Group reaffirmed a “hold” rating and issued a $44.00 target price on shares of Mednax in a report on Friday, November 3rd. Finally, Zacks Investment Research raised Mednax from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $54.50.

WARNING: This report was originally reported by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.watchlistnews.com/bbt-securities-llc-sells-5415-shares-of-mednax-inc-md/1741296.html.

Mednax Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mednax, Inc (NYSE:MD).

Institutional Ownership by Quarter for Mednax (NYSE:MD)

Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.